Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03843775 · ClinicalTrials.gov registry record · Phase 1
A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers
A Phase 1 study of Advanced BRAF Mutant Cancers, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
- 4
- Study locations
NCT03843775: Completed Phase 1 study of Advanced BRAF Mutant Cancers, sponsored by Memorial Sloan Kettering Cancer Center.
NCT03843775 is a Phase 1 study of Advanced BRAF Mutant Cancers that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 17 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (72% lower). The trial reports 4 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03843775, a Phase 1 study of Advanced BRAF Mutant Cancers, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
- 4
- Study locations
Study Summary
The goal of this trial is to test the safety and efficacy of an innovative combination aimed to more profoundly inhibit ERK signaling in tumors.
Primary Outcome
National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), Version 5,
Conditions Studied
Interventions
- DRUG Binimetinib
- DRUG Encorafenib
Study Locations (4)
New York
- Memorial Sloan Kettering Cancer Center @ Suffolk (Limited protocol activity) - Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities) - Harrison
- Memorial Sloan Kettering Cancer Center - New York
New Jersey
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) - Middletown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2019-02-14 |
| Est. Completion | 2023-09-02 |
| Phase | Phase 1 |
What the finished NCT03843775 record still lists
NCT03843775 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (72% lower).
The record links to 1 condition, with Advanced BRAF Mutant Cancers appearing as the primary indexed condition, and to 2 interventions - of which Binimetinib is the first listed.
NCT03843775 reports a single indexed study location in New York, New Jersey.
Frequently Asked Questions
What is clinical trial NCT03843775 about?
NCT03843775 is a clinical study titled "A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers". The goal of this trial is to test the safety and efficacy of an innovative combination aimed to more profoundly inhibit ERK signaling in tumors.
What is the current status of trial NCT03843775?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2019-02-14. Estimated completion is 2023-09-02.
What conditions does trial NCT03843775 study?
This clinical trial studies the following conditions: Advanced BRAF Mutant Cancers.
What interventions are being tested in trial NCT03843775?
The interventions under investigation include: Binimetinib (DRUG), Encorafenib (DRUG).
Who is sponsoring clinical trial NCT03843775?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03843775 being conducted?
This trial has 4 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03843775's enrollment target sits among peer trials
17 1785th of 2000 higher than 215 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02090140 · 17 participants · NA
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
- NCT03317860 · 17 participants · NA
Improving Measurement and Treatment of Post-stroke Neglect
- NCT04356469 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
- NCT04414046 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI